Ganoderic acid DM: Anti-androgenic osteoclastogenesis inhibitor

Bioorganic & Medicinal Chemistry Letters

Prostate cancer is the most common cancer in men in Western countries, with a high incidence of bone metastasis. Ganoderic acid DM, with 5??-reductase inhibitory and androgen receptor (AR) binding activity, isolated from the ethanol extracts of Ganoderma lucidum, can inhibit prostate cancer cell growth and block osteoclastogenesis.